• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality.

作者信息

Nasrallah Henry A

机构信息

Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, Saint Louis, MO, USA.

出版信息

Schizophr Res. 2018 Jul;197:69-70. doi: 10.1016/j.schres.2018.02.004. Epub 2018 Mar 3.

DOI:10.1016/j.schres.2018.02.004
PMID:29506767
Abstract
摘要

相似文献

1
Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality.注射用长效第二代抗精神病药物的三大优势：预防复发、神经保护及降低死亡率。
Schizophr Res. 2018 Jul;197:69-70. doi: 10.1016/j.schres.2018.02.004. Epub 2018 Mar 3.
2
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.长效注射用利培酮用于预防精神分裂症近期首次发作后的复发及控制突破性症状：一项随机临床试验
JAMA Psychiatry. 2015 Aug;72(8):822-9. doi: 10.1001/jamapsychiatry.2015.0270.
3
Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.棕榈酸帕利哌酮单月制剂对精神分裂症患者复发预防的影响：一项为期一年、开放性研究的事后分析，按药物依从性分层。
J Psychopharmacol. 2018 Jun;32(6):691-701. doi: 10.1177/0269881118772449. Epub 2018 May 16.
4
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.精神分裂症或双相情感障碍患者中长效注射用与口服抗精神病药物的用药依从性及停药情况
J Med Econ. 2018 Feb;21(2):127-134. doi: 10.1080/13696998.2017.1379412. Epub 2017 Sep 29.
5
[Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].我们在精神分裂症中预防抗精神病药物复发的临床实践真的是以证据为基础的吗？
Neuropsychiatr. 2010;24(1):14-26.
6
Long-acting injectable antipsychotics: evidence of effectiveness and use.长效注射用抗精神病药：有效性和使用证据。
Can J Psychiatry. 2013 May;58(5 Suppl 1):5S-13S. doi: 10.1177/088740341305805s02.
7
Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).精神分裂症患者的管理模式（Mo.Ma）：通过长效注射用抗精神病药物（LAIs）进行危机控制、维持治疗、预防复发和康复。
Riv Psichiatr. 2016 Mar-Apr;51(2):47-59. doi: 10.1708/2246.24194.
8
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.长效注射用帕利哌酮棕榈酸酯：疗效与安全性综述
Psychopharmacol Bull. 2017 May 15;47(2):42-52.
9
"Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".药物报销政策对处方的影响：复发型精神分裂症患者中一种新上市长效注射用抗精神病药物的案例研究
Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):95-104. doi: 10.1002/pds.4354. Epub 2017 Nov 23.
10
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.长效注射用抗精神病药物治疗精神分裂症：预防复发的作用。
Expert Opin Pharmacother. 2010 Oct;11(14):2301-17. doi: 10.1517/14656566.2010.499125.

引用本文的文献

1
Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes.长效注射用第二代抗精神病药物治疗重度精神分裂症患者：剂量、血药浓度及治疗效果
Biomedicines. 2024 Jan 12;12(1):165. doi: 10.3390/biomedicines12010165.
2
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).第二代抗精神病药物剂量国际共识研究（ICSAD-2）。
J Psychopharmacol. 2023 Oct;37(10):982-991. doi: 10.1177/02698811231205688. Epub 2023 Oct 16.
3
Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety.
重度精神分裂症患者中血浆水平及对不同剂量月用阿立哌唑和三月用帕利哌酮的反应。治疗依从性、有效性、耐受性和安全性。
Neuropsychiatr Dis Treat. 2023 Oct 5;19:2093-2103. doi: 10.2147/NDT.S425516. eCollection 2023.
4
Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study.长效注射第二代抗精神病药物对精神分裂症临床、认知及社会领域的疗效：一项前瞻性自然主义研究的结果
Brain Sci. 2023 Mar 29;13(4):577. doi: 10.3390/brainsci13040577.
5
The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage-A 5-Year Follow-Up.现实世界中第二代抗精神病药物在重度精神分裂症患者中的应用：给药途径和剂量的作用——一项5年随访研究
Biomedicines. 2022 Dec 24;11(1):42. doi: 10.3390/biomedicines11010042.
6
Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up.与标准治疗相比，针对重度精神分裂症患者的更个性化、病例管理和多组分治疗的有效性：十年随访
J Pers Med. 2022 Jul 4;12(7):1101. doi: 10.3390/jpm12071101.
7
The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study.对长效注射剂临床反应中药物态度和治疗依从性的作用：STAR网络长效注射剂研究的结果
Front Psychiatry. 2021 Dec 16;12:784366. doi: 10.3389/fpsyt.2021.784366. eCollection 2021.
8
Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN).长效注射用抗精神病药物起始指数（ROLIN）的评级机会。
Front Psychiatry. 2021 Dec 7;12:767756. doi: 10.3389/fpsyt.2021.767756. eCollection 2021.
9
Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.与每月注射棕榈酸帕利哌酮（PP1M）相比，每三个月注射一次棕榈酸帕利哌酮（PP3M）治疗重度精神分裂症患者的2年治疗依从性、有效性及满意度
J Clin Med. 2021 Apr 1;10(7):1408. doi: 10.3390/jcm10071408.
10
Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics.将自杀预防纳入长效注射用第二代抗精神病药物的三大优势之中。
Front Psychiatry. 2020 Jan 14;10:931. doi: 10.3389/fpsyt.2019.00931. eCollection 2019.